Originally published as JCO Early Release 10.1200/JCO.2005.02.520 on June 27 2005

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Freidlin, B. Articles by Simon, R. Search for Related Content PubMed PubMed Citation Articles by Freidlin, B. Articles by Simon, R. Related Articles Related Editorial Social Bookmarking                            What's this?

Evaluation of Randomized Discontinuation Design

From the Biometric Research Branch, National Cancer Institute, Bethesda, MD

Address reprint requests to Boris Freidlin, PhD, Biometric Research Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, 6130 Executive Blvd, EPN 8122, MSC 7434, Bethesda, MD 20892-7434; e-mail: freidlinb{at}ctep.nci.nih.gov

PURPOSE: Single-arm phase II trials may not be appropriate for testing cytostatic agents. We evaluate two kinds of randomized designs for the early development of target-based cytostatic agents.

METHODS: We compared power of the randomized discontinuation and upfront randomization designs under two models for the treatment effect of targeted cytostatic agents.

RESULTS: The randomized discontinuation design is not as efficient as upfront randomization if treatment has a fixed effect on tumor growth rate or if treatment benefit is restricted to slower-growing tumors. On the other hand, the randomized discontinuation design can be advantageous under a model where only a subset of patients, those expressing the molecular target, is sensitive to the agent. To achieve efficiency, the design parameters must be carefully structured to provide adequate enrichment of the randomly assigned patients.

CONCLUSION: With careful planning, the randomized discontinuation designs can be useful in some settings in the early development of targeted agents where a reliable assay to select patients expressing the target is not available.

Authors' disclosures of potential conflicts of interest are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

Related Editorial

• Enrichment Designs: Efficiency in Development of Cancer Treatments
  Robert J. Temple
  JCO 2005 23: 4838-4839 [Full Text]

This article has been cited by other articles:

				L. Rubinstein, J. Crowley, P. Ivy, M. LeBlanc, and D. Sargent Randomized Phase II Designs Clin. Cancer Res., March 15, 2009; 15(6): 1883 - 1890. [Abstract] [Full Text] [PDF]

				T. Lundeberg and I. Lund Treatment recommendations should take account of individual patient variation not just group responses Acupunct Med, March 1, 2009; 27(1): 31 - 32. [Abstract] [Full Text] [PDF]

				R. Labianca, M. Garassino, and V. Torri Predicting response of molecular targeted therapies: a still possible challenge? Ann. Onc., May 1, 2008; 19(5): 829 - 830. [Full Text] [PDF]

				W. M. Stadler Tumor Burden Endpoints and Phase II Clinical Trial Design ASCO Educational Book, January 1, 2008; 2008(1): 89 - 93. [Abstract] [Full Text] [PDF]

				W. M. Stadler The randomized discontinuation trial: a phase II design to assess growth-inhibitory agents Mol. Cancer Ther., April 1, 2007; 6(4): 1180 - 1185. [Abstract] [Full Text] [PDF]

				D. H. Johnson Targeted therapies in combination with chemotherapy in non-small cell lung cancer. Clin. Cancer Res., July 15, 2006; 12(14): 4451s - 4457s. [Abstract] [Full Text] [PDF]

				A. Morabito, E. De Maio, M. Di Maio, N. Normanno, and F. Perrone Tyrosine Kinase Inhibitors of Vascular Endothelial Growth Factor Receptors in Clinical Trials: Current Status and Future Directions Oncologist, July 1, 2006; 11(7): 753 - 764. [Abstract] [Full Text] [PDF]

				R. Gray, J. Manola, S. Saxman, J. Wright, J. Dutcher, M. Atkins, M. Carducci, W. See, C. Sweeney, G. Liu, et al. Phase II Clinical Trial Design: Methods in Translational Research from the Genitourinary Committee at the Eastern Cooperative Oncology Group. Clin. Cancer Res., April 1, 2006; 12(7): 1966 - 1969. [Abstract] [Full Text] [PDF]

				B. Freidlin and R. Simon Adaptive Signature Design: An Adaptive Clinical Trial Design for Generating and Prospectively Testing A Gene Expression Signature for Sensitive Patients Clin. Cancer Res., November 1, 2005; 11(21): 7872 - 7878. [Abstract] [Full Text] [PDF]

				R. J. Temple Enrichment Designs: Efficiency in Development of Cancer Treatments J. Clin. Oncol., August 1, 2005; 23(22): 4838 - 4839. [Full Text] [PDF]